Kayce M. Shealy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kayce M. Shealy has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
David H. Eagerton
2 shared publications- Amy Buros Stein
Midwestern University, Glendale, AZ, United States
1 shared publication - Amy Hynes
Presbyterian College School of Pharmacy, Clinton, SC, United States
1 shared publication - Andrew S. Bzowyckyj
National Kidney Foundation New York New York USA
1 shared publication Anna S. Wyatt
1 shared publication- Brooke L. Griffin
Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA
1 shared publication
Latest Publications
- 16 February 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (4) , 481-489
Endocrine pharmacotherapy education in United States colleges and schools of pharmacy
Background: As Doctor of Pharmacy (Pharm.D.) curricula are revised, it is important to identify what to retain and prioritize; previous studies have not evaluated the endocrine content within curricula at United States (U.S.) schools and colleges of pharmacy.Objective: To determine the breadth of endocrine instruction and assessment within preadvanced pharmacy practice experience (pre‐APPE) coursework in the clinical sciences across U.S. Pharm.D. programs.Methods: A cross‐sectional survey‐based study of U.S. schools and colleges of pharmacy was completed evaluating the 2018 to 19 academic year. Data were summarized using descriptive statistics. Categorical variables were assessed using Chi‐square or Fisher's exact tests and ordinal variables were evaluated using Mann‐Whitney U and Kruskal‐Wallis tests, with a priori significance set at .05. The study was approved by the Presbyterian College Institutional Review Board with exempt status.Results: Fifty‐eight of 142 (40.8%) programs participated. Contact hours for required endocrine content varied, with 57% responding with more than 30 hours. Among 15 topics, only types 1 and 2 diabetes and thyroid disorders were required at all programs. For two‐thirds of the topics, the perception of topic importance differed between programs that cover and those that do not cover the topic (P <.05). The most common assessment strategies included case studies (100%), multiple choice questions (97%), SOAP note writing, and skills demonstrations (72% each). The most common diabetes‐related Entrustable Professional Activities (EPAs) were: evaluating drug therapy, following guidelines, and educating patients (98% each). The most commonly cited barrier to including more endocrine topics was lack of curricular time (88%).Conclusions: Inconsistency in endocrine content within curricula at U.S. PharmD programs includes topics covered, contact hours, and perception of topic importance. Respondents consistently noted their methods appropriately educated student pharmacists to develop diabetes‐related EPAs. Development of a standardized endocrine curricula could establish minimal competencies for APPE‐readiness.
- 16 February 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (4) , 481-489
Endocrine pharmacotherapy education in United States colleges and schools of pharmacy
Background: As Doctor of Pharmacy (Pharm.D.) curricula are revised, it is important to identify what to retain and prioritize; previous studies have not evaluated the endocrine content within curricula at United States (U.S.) schools and colleges of pharmacy.Objective: To determine the breadth of endocrine instruction and assessment within preadvanced pharmacy practice experience (pre‐APPE) coursework in the clinical sciences across U.S. Pharm.D. programs.Methods: A cross‐sectional survey‐based study of U.S. schools and colleges of pharmacy was completed evaluating the 2018 to 19 academic year. Data were summarized using descriptive statistics. Categorical variables were assessed using Chi‐square or Fisher's exact tests and ordinal variables were evaluated using Mann‐Whitney U and Kruskal‐Wallis tests, with a priori significance set at .05. The study was approved by the Presbyterian College Institutional Review Board with exempt status.Results: Fifty‐eight of 142 (40.8%) programs participated. Contact hours for required endocrine content varied, with 57% responding with more than 30 hours. Among 15 topics, only types 1 and 2 diabetes and thyroid disorders were required at all programs. For two‐thirds of the topics, the perception of topic importance differed between programs that cover and those that do not cover the topic (P <.05). The most common assessment strategies included case studies (100%), multiple choice questions (97%), SOAP note writing, and skills demonstrations (72% each). The most common diabetes‐related Entrustable Professional Activities (EPAs) were: evaluating drug therapy, following guidelines, and educating patients (98% each). The most commonly cited barrier to including more endocrine topics was lack of curricular time (88%).Conclusions: Inconsistency in endocrine content within curricula at U.S. PharmD programs includes topics covered, contact hours, and perception of topic importance. Respondents consistently noted their methods appropriately educated student pharmacists to develop diabetes‐related EPAs. Development of a standardized endocrine curricula could establish minimal competencies for APPE‐readiness.
- 1 January 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (1) , 27-34
Pharmacist self-perception of readiness to prescribe hormonal contraception and additional training needs
- 1 January 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (1) , 27-34
Pharmacist self-perception of readiness to prescribe hormonal contraception and additional training needs
- 1 July 2019
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 59 (4) , 575-578
Trends in potentially abused medications returned during medication take-back days
- 1 July 2019
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 59 (4) , 575-578
Trends in potentially abused medications returned during medication take-back days
- 8 March 2019
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 32 (2) , 209-217
Patterns of Diabetes Screening and Prediabetes Treatment during Office Visits in the US
Introduction: The American Diabetes Association recommends annual screenings for prediabetes if the patient meets the suggested requirements. The overall prevalence of prediabetes has decreased from an estimated 86 million adults in 2012 to 84.1 million adults in 2015 in the United States. Along with lifestyle modifications, the use of metformin as a treatment option or in combination has shown a decrease in weight and health care costs. This study was designed to review the prevalence of screening and treatment of prediabetes in the United States by using the National Ambulatory Medical Care Survey, as well as identify any factors associated with screenings and treatment. Methods: The National Ambulatory Medical Care Survey was used to examine a study sample of office visits between 2012 and 2015, reviewing the prevalence of screenings and lab services ordered or provided at each patient visit. Inclusion criteria consisted of the recommendations given by the American Diabetes Association including any patient ≥45 years or adult patient 2 and an additional risk factor. Patients with a previous diagnosis of diabetes were excluded from the sample. Results: A total of 105,721 office visits (2012 to 2015) were included in the analysis. The diabetes screening prevalence increased from 10% in 2012 to 13.4% in 2015. Metformin (n = 140, 76.1%) was the most common antidiabetic medication prescribed to treat prediabetes. Conclusions: The prevalence of diabetes screening during office visits remained lower than 15% between 2012 and 2015 in the United States. Physicians primarily prescribe lifestyle modifications, including a healthy diet and exercise, with metformin being used in some cases for the prevention of diabetes.
- 8 March 2019
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 32 (2) , 209-217
Patterns of Diabetes Screening and Prediabetes Treatment during Office Visits in the US
Introduction: The American Diabetes Association recommends annual screenings for prediabetes if the patient meets the suggested requirements. The overall prevalence of prediabetes has decreased from an estimated 86 million adults in 2012 to 84.1 million adults in 2015 in the United States. Along with lifestyle modifications, the use of metformin as a treatment option or in combination has shown a decrease in weight and health care costs. This study was designed to review the prevalence of screening and treatment of prediabetes in the United States by using the National Ambulatory Medical Care Survey, as well as identify any factors associated with screenings and treatment. Methods: The National Ambulatory Medical Care Survey was used to examine a study sample of office visits between 2012 and 2015, reviewing the prevalence of screenings and lab services ordered or provided at each patient visit. Inclusion criteria consisted of the recommendations given by the American Diabetes Association including any patient ≥45 years or adult patient 2 and an additional risk factor. Patients with a previous diagnosis of diabetes were excluded from the sample. Results: A total of 105,721 office visits (2012 to 2015) were included in the analysis. The diabetes screening prevalence increased from 10% in 2012 to 13.4% in 2015. Metformin (n = 140, 76.1%) was the most common antidiabetic medication prescribed to treat prediabetes. Conclusions: The prevalence of diabetes screening during office visits remained lower than 15% between 2012 and 2015 in the United States. Physicians primarily prescribe lifestyle modifications, including a healthy diet and exercise, with metformin being used in some cases for the prevention of diabetes.
- 1 October 2018
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 82 (8) , 6701
Incorporating an Entrepreneurial Certificate into the Pharmacy Curriculum
Objective: Describe the implementation and assessment of an entrepreneurial certificate program within an elective.Methods: An entrepreneurial certificate program through the Kauffman Foundation was integrated within an entrepreneurial elective to provide students at Presbyterian College School of Pharmacy to receive more in depth training regarding entrepreneurial skills. A pre-/post-survey was administered to assess knowledge and skills obtained.Results: Thirty-three students completed the pre-/post-survey within the entrepreneurial elective. By completing the entrepreneurial certificate, most students increased their knowledge and skills in entrepreneurism.Conclusion: Incorporating an entrepreneurial certificate program into the pharmacy curriculum increases student knowledge regarding entrepreneurial principles.
- 1 October 2018
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 82 (8) , 6701
Incorporating an Entrepreneurial Certificate into the Pharmacy Curriculum
Objective: Describe the implementation and assessment of an entrepreneurial certificate program within an elective.Methods: An entrepreneurial certificate program through the Kauffman Foundation was integrated within an entrepreneurial elective to provide students at Presbyterian College School of Pharmacy to receive more in depth training regarding entrepreneurial skills. A pre-/post-survey was administered to assess knowledge and skills obtained.Results: Thirty-three students completed the pre-/post-survey within the entrepreneurial elective. By completing the entrepreneurial certificate, most students increased their knowledge and skills in entrepreneurism.Conclusion: Incorporating an entrepreneurial certificate program into the pharmacy curriculum increases student knowledge regarding entrepreneurial principles.
- Open Access
- 28 March 2017
- Published by SAGE Publications in Respiratory Care
- Vol. 62 (7) , 882-887
Evaluation of the Prevalence and Effectiveness of Education on Metered-Dose Inhaler Technique
BACKGROUND: The objectives of this study were: (1) to assess the prevalence of and types of education methods provided to participants who use a metered-dose inhaler (MDI), (2) to determine the prevalence of MDI misuse in adults using objective and subjective assessments, and (3) to determine whether any associations exist between the education method and the participant's ability to properly use an MDI. METHODS: Adult participants who had a current or previous history of MDI use were recruited from retail pharmacies and physician offices in Laurens County, South Carolina. Exclusion criteria included the use of an MDI spacer, inability to speak/understand English, or current acute respiratory illness. Participants completed a survey regarding inhaler use and previous education, a subjective checklist assessment by demonstrating use of an MDI, and an objective assessment by using the Aerosol Inhalation Monitor (AIM). RESULTS: Of 100 participants, 25% reported never having received education about inhaler technique, and 94% were found to have insufficient MDI technique. No association between the method of education and successful MDI technique with the AIM was identified ( P = .31). Participants were less likely to correctly use the AIM if they missed >3 steps in the subjective assessment. ( P = .032). CONCLUSIONS: Although most participants received inhaler education, inhaler misuse was very common. No associations were found regarding method of education and proper inhaler technique.
- 28 March 2017
- Published by SAGE Publications in Respiratory Care
- Vol. 62 (7) , 882-887
Open AccessEvaluation of the Prevalence and Effectiveness of Education on Metered-Dose Inhaler Technique
BACKGROUND: The objectives of this study were: (1) to assess the prevalence of and types of education methods provided to participants who use a metered-dose inhaler (MDI), (2) to determine the prevalence of MDI misuse in adults using objective and subjective assessments, and (3) to determine whether any associations exist between the education method and the participant's ability to properly use an MDI. METHODS: Adult participants who had a current or previous history of MDI use were recruited from retail pharmacies and physician offices in Laurens County, South Carolina. Exclusion criteria included the use of an MDI spacer, inability to speak/understand English, or current acute respiratory illness. Participants completed a survey regarding inhaler use and previous education, a subjective checklist assessment by demonstrating use of an MDI, and an objective assessment by using the Aerosol Inhalation Monitor (AIM). RESULTS: Of 100 participants, 25% reported never having received education about inhaler technique, and 94% were found to have insufficient MDI technique. No association between the method of education and successful MDI technique with the AIM was identified ( P = .31). Participants were less likely to correctly use the AIM if they missed >3 steps in the subjective assessment. ( P = .032). CONCLUSIONS: Although most participants received inhaler education, inhaler misuse was very common. No associations were found regarding method of education and proper inhaler technique.
- 1 March 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (2) , 324-331
Student pharmacist perceived benefit of a sequential training model for health testing
- 1 March 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (2) , 324-331
Student pharmacist perceived benefit of a sequential training model for health testing
- 11 August 2016
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 11 (5) , 373-378
Liraglutide, GLP-1 receptor agonist, for chronic weight loss
Introduction: Since 1990, the prevalence of obesity has been steadily increasing in the United States. Over the past four years, new medications have become approved and available, allowing for more options in the management of chronic weight loss among overweight or obese patients. This review article summarizes the efficacy, safety, and clinical attributes of liraglutide among overweight or obese patients with or without comorbidities. Areas covered: A MEDLINE search, from 1970 to June 2016, was conducted using key terms—glucagon-like peptide-1 receptor agonist, liraglutide, overweight, and obesity. Published clinical trials, in the English-language and with primary endpoints related to weight loss, were reviewed and critiqued in this article. Expert commentary: Available as a subcutaneous daily injection, liraglutide is the first glucagon-like peptide-1 (GLP-1) receptor agonist indicated for obesity management, as adjunct therapy with lifestyle and behavioral modifications. Liraglutide 3 mg daily has been associated with greater weight loss than placebo or orlistat in patients without type 2 diabetes. Additionally, liraglutide has resulted in reductions in waist circumference, systolic and diastolic blood pressure, and improvements in lipid panel among overweight and obese patients with and without type 2 diabetes.
- 11 August 2016
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 11 (5) , 373-378
Liraglutide, GLP-1 receptor agonist, for chronic weight loss
Introduction: Since 1990, the prevalence of obesity has been steadily increasing in the United States. Over the past four years, new medications have become approved and available, allowing for more options in the management of chronic weight loss among overweight or obese patients. This review article summarizes the efficacy, safety, and clinical attributes of liraglutide among overweight or obese patients with or without comorbidities. Areas covered: A MEDLINE search, from 1970 to June 2016, was conducted using key terms—glucagon-like peptide-1 receptor agonist, liraglutide, overweight, and obesity. Published clinical trials, in the English-language and with primary endpoints related to weight loss, were reviewed and critiqued in this article. Expert commentary: Available as a subcutaneous daily injection, liraglutide is the first glucagon-like peptide-1 (GLP-1) receptor agonist indicated for obesity management, as adjunct therapy with lifestyle and behavioral modifications. Liraglutide 3 mg daily has been associated with greater weight loss than placebo or orlistat in patients without type 2 diabetes. Additionally, liraglutide has resulted in reductions in waist circumference, systolic and diastolic blood pressure, and improvements in lipid panel among overweight and obese patients with and without type 2 diabetes.
- 27 October 2015
- Published by Taylor & Francis in Health Communication
- Vol. 31 (6) , 679-687
Utilization of the Newest Vital Sign (NVS) in Practice in the United States
Health literacy refers to the ability of a patient to obtain, communicate, process, and understand basic information related to health and services. It is estimated that the majority of adult Americans may have difficulty understanding health information. In addition, limited health literacy of patients is linked to over $100 billion in health care costs. Measurement of health literacy may aid in improving communication with patients, and thus to improving outcomes and decreasing costs. The Newest Vital Sign (NVS) is a tool that has been used to assess health literacy in a variety of patients. It has been validated against other measures including the Test of Functional Health Literacy in Adults (TOFHLA). Patients are categorized as high likelihood of limited health literacy, possible limited health literacy, or adequate literacy. The NVS has been used in a variety of settings and tested among a wide range of patient groups. The most common setting for use is in primary care, probably due to the relatively quick assessment of health literacy (within 3 minutes). The NVS has been used in Caucasians, African Americans, Hispanics, and several other ethnicities. Assessment with the NVS has been conducted in adult patients across the age continuum, and with several different health conditions, including diabetes, kidney disease, and pain. This article seeks to review the published uses to date and to provide suggestions for potential uses of the NVS.
- 27 October 2015
- Published by Taylor & Francis in Health Communication
- Vol. 31 (6) , 679-687
Utilization of the Newest Vital Sign (NVS) in Practice in the United States
Health literacy refers to the ability of a patient to obtain, communicate, process, and understand basic information related to health and services. It is estimated that the majority of adult Americans may have difficulty understanding health information. In addition, limited health literacy of patients is linked to over $100 billion in health care costs. Measurement of health literacy may aid in improving communication with patients, and thus to improving outcomes and decreasing costs. The Newest Vital Sign (NVS) is a tool that has been used to assess health literacy in a variety of patients. It has been validated against other measures including the Test of Functional Health Literacy in Adults (TOFHLA). Patients are categorized as high likelihood of limited health literacy, possible limited health literacy, or adequate literacy. The NVS has been used in a variety of settings and tested among a wide range of patient groups. The most common setting for use is in primary care, probably due to the relatively quick assessment of health literacy (within 3 minutes). The NVS has been used in Caucasians, African Americans, Hispanics, and several other ethnicities. Assessment with the NVS has been conducted in adult patients across the age continuum, and with several different health conditions, including diabetes, kidney disease, and pain. This article seeks to review the published uses to date and to provide suggestions for potential uses of the NVS.
- 7 August 2014
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 30 (5) , 147-150
The Needs and Opportunities for Medication Disposal Programs
The continued increase in the usage of medications has led to a variety of negative consequences, including adverse effects on our environment and an increase in misuse/abuse of these products. Improper disposal of unused medications results in significant effects to wildlife and the potential to adversely affect human cells. Increases in misuse/abuse have resulted in significant increases in emergency department visits for drug-related issues. Drug overdose is now the leading cause of accidental death in the United States. Education of both health care providers and the general public about these issues and the proper disposal of unused medications is crucial.
- 7 August 2014
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 30 (5) , 147-150
The Needs and Opportunities for Medication Disposal Programs
The continued increase in the usage of medications has led to a variety of negative consequences, including adverse effects on our environment and an increase in misuse/abuse of these products. Improper disposal of unused medications results in significant effects to wildlife and the potential to adversely affect human cells. Increases in misuse/abuse have resulted in significant increases in emergency department visits for drug-related issues. Drug overdose is now the leading cause of accidental death in the United States. Education of both health care providers and the general public about these issues and the proper disposal of unused medications is crucial.